Format

Send to

Choose Destination
See comment in PubMed Commons below
ScientificWorldJournal. 2011 Apr 5;11:742-8. doi: 10.1100/tsw.2011.72.

Methods to predict and lower the risk of prostate cancer.

Author information

1
Department of Urology, University of Texas Health Science Center, San Antonio, USA.

Abstract

Chemoprevention for prostate cancer (PCa) continues to generate interest from both physicians and the patient population. The goal of chemoprevention is to stop the malignant transformation of prostate cells into cancer. Multiple studies on different substances ranging from supplements to medical therapy have been undertaken. Thus far, only the studies on 5 alpha-reductase inhibitors (the Prostate Cancer Prevention Trial [PCPT] and Reduction by Dutasteride of Prostate Cancer Events [REDUCE] trial) have demonstrated a reduction in the risk of PCa, while results from the Selenium and Vitamin E Cancer Prevention Trial (SELECT) concluded no decreased risk for PCa with selenium or vitamin E.

PMID:
21479345
PMCID:
PMC5720086
DOI:
10.1100/tsw.2011.72
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Hindawi Publishing Corporation Icon for PubMed Central
    Loading ...
    Support Center